Literature DB >> 34910237

The diagnostic value of contrast-enhanced ultrasound LI-RADS for hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis B.

Dan Yang1, Hong Hu2, Rui Li3, Chun-Lin Tang4, Kuan-Sheng Ma5, De-Yu Guo6.   

Abstract

PURPOSE: To explore the diagnostic value of American College of Radiology Contrast-Enhanced Ultrasound-Liver Imaging Reporting and Data System (ACR-CEUS-LI-RADS) for hepatocellular carcinoma (HCC) in patients with cirrhosis and chronic hepatitis B.
METHODS: A total of 205 patients at high risk of HCC with solitary hepatic nodule were enrolled and retrospectively analyzed. All patients were over 18 years old and had a single lesion with a diameter < 50 mm. Lesions were categorized according to size and contrast enhancement patterns in the arterial, portal venous and late phases. Diagnostic efficacy of CEUS LI-RADS for HCC, and the rate of non-HCC malignancies in the LR-M class were compared between patients with cirrhosis and chronic hepatitis B.
RESULTS: Of all 205 nodules (median nodule size was 34 mm), 142 (69.3%) were HCC. Of the 127 (61.9%) LR-5 category nodules, 95.8% (92/96) nodules were corresponded to HCC in cirrhosis, while 61.3% (19/31) nodules were corresponded to HCC in chronic hepatitis B (P = 0.000). Positive predictive value (PPV) of LR-5 category for HCC was 95.8% in cirrhosis and 61.3% in chronic hepatitis B (P = 0.000). More category of LR-4 nodules were proved to be HCC in patients with cirrhosis than chronic hepatitis B (80.0% vs 8.3%, P = 0.000). Of 41 LR-M category nodules, more non-HCC malignancies were found in chronic hepatitis B (76.0%) than that in cirrhosis (25.0%, P = 0.001).
CONCLUSIONS: The LR-5 category is highly specific for the diagnosis of HCC in patients with cirrhosis. However, LR-5 category nodules require further CT or MRI examination or histological confirmation in patients with chronic hepatitis B for its unsatisfactory PPV for HCC.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Chronic hepatitis B; Cirrhosis; Contrast-enhanced ultrasound LI-RADS; Hepatocellular carcinoma

Mesh:

Substances:

Year:  2021        PMID: 34910237     DOI: 10.1007/s00261-021-03345-9

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  2 in total

1.  Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver--update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS.

Authors:  M Claudon; C F Dietrich; B I Choi; D O Cosgrove; M Kudo; C P Nolsøe; F Piscaglia; S R Wilson; R G Barr; M C Chammas; N G Chaubal; M-H Chen; D A Clevert; J M Correas; H Ding; F Forsberg; J B Fowlkes; R N Gibson; B B Goldberg; N Lassau; E L S Leen; R F Mattrey; F Moriyasu; L Solbiati; H-P Weskott; H-X Xu
Journal:  Ultraschall Med       Date:  2012-11-05       Impact factor: 6.548

2.  Factors Affecting the Enhancement Patterns of Intrahepatic Cholangiocarcinoma (ICC) on Contrast-Enhanced Ultrasound (CEUS) and their Pathological Correlations in Patients with a Single Lesion.

Authors:  M X Yuan; R Li; X H Zhang; C L Tang; Y L Guo; D Y Guo; M K Luo
Journal:  Ultraschall Med       Date:  2015-04-28       Impact factor: 6.548

  2 in total
  1 in total

1.  Risk Stratification and Distribution of Hepatocellular Carcinomas in CEUS and CT/MRI LI-RADS: A Meta-Analysis.

Authors:  Yan Zhou; Zhengyi Qin; Jianmin Ding; Lin Zhao; Ying Chen; Fengmei Wang; Xiang Jing
Journal:  Front Oncol       Date:  2022-03-29       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.